Download Antiviral Agents: Mechanisms, Classification, and Therapeutic Applications and more Exams Advanced Education in PDF only on Docsity!
OVERVIEW OF ANTIVIRAL AGENTS
AND THEIR MECHANISMS, 2025/
OUTLINE 100%
OVERVIEW OF ANTIVIRAL AGENTS
Classification of Antiviral Drugs Antiviral agents are categorized into five main classes based on their mechanisms of action against viruses, particularly HIV. The first three classes inhibit enzymes essential for HIV replication:
- Reverse Transcriptase Inhibitors (RTIs): Subdivided into NRTIs and NNRTIs.
- Integrase Strand Transfer Inhibitors (INSTIs): Block the integration of viral DNA into the host genome.
- Protease Inhibitors (PIs): Prevent the maturation of viral proteins, essential for viral infectivity. The last two classes block viral entry into host cells:
- Fusion Inhibitors: Prevent the fusion of the viral envelope with the host cell membrane.
- CCR5 Antagonists: Block the CCR5 co-receptor on CD4 cells, inhibiting HIV entry.
PROTEASE INHIBITORS (PIS)
Mechanism of Action (MOA)
Protease inhibitors (PIs) inhibit the HIV protease enzyme, which is crucial for cleaving polyproteins into functional enzymes and structural proteins. By preventing the cleavage of these polyproteins, PIs ensure that the virus remains immature and noninfectious. This action effectively halts the maturation process of HIV, thereby reducing viral load in the body. Adverse Effects Common adverse effects of PIs include hyperglycemia, diabetes, lipodystrophy, hyperlipidemia, increased bleeding in hemophilia patients, elevation of serum transaminases, and decreased cardiac conduction velocity. Hyperglycemia/Diabetes: Onset typically occurs after 2 months of use; managed with insulin or oral agents like metformin. Patients should monitor for symptoms such as polydipsia, polyphagia, and polyuria. Lipodystrophy: Characterized by fat redistribution, leading to accumulation in the abdomen and loss in extremities; the underlying mechanism remains unclear. Hyperlipidemia: PIs can elevate cholesterol and triglyceride levels, increasing the risk of cardiovascular events and pancreatitis; monitoring lipid levels is essential. Increased Bleeding: Particularly in hemophilia patients, with serious bleeds possible; dosage of coagulation factors may need adjustment. Elevation of Serum Transaminases: Indicates potential liver injury; caution is advised in patients with pre-existing liver conditions. Drug Interactions
Bictegravir and elvitegravir are available only in combination with other drugs, enhancing their therapeutic efficacy.
CHEMOKINE RECEPTOR 5 ANTAGONISTS
(CCR5 ANTAGONISTS)
Mechanism of Action CCR5 antagonists block the entry of HIV into CD4 T-cells by binding to the CCR5 receptor, which some strains of HIV require for entry. Maraviroc (MVC) is the first and only approved CCR antagonist, effective primarily against CCR5-tropic HIV strains. Therapeutic Use Indicated for use in combination with other antiretroviral agents for patients aged 16 and older infected with CCR5- tropic HIV-1 strains. Prior to use, a test must confirm that the infecting HIV strain is CCR5 tropic, as maraviroc is not effective against other strains. Adverse Effects Common side effects include cough, dizziness, pyrexia, rash, abdominal pain, musculoskeletal symptoms, and upper respiratory tract infections. Monitoring for these effects is essential to ensure patient safety during treatment.
HIV AND CCR5 TROPIC STRAINS
Overview of CCR5 Tropic HIV
CCR5 tropic HIV strains require the CCR5 co-receptor for entry into host cells, accounting for 50-60% of HIV infections. Understanding the mechanism of entry is crucial for developing targeted therapies against HIV. The presence of CCR5 tropic strains can influence treatment decisions and patient management. Maraviroc: Mechanism and Therapeutic Use Maraviroc is a CCR5 antagonist that blocks HIV entry by preventing the virus from binding to the CCR5 receptor. Initially approved for treatment-experienced patients, it is now also indicated for treatment-naïve patients with CCR5- tropic HIV-1. A test to confirm CCR5 tropic strain is mandatory before starting treatment with maraviroc. Adverse Effects and Monitoring Common side effects include cough, dizziness, pyrexia, rash, and abdominal pain, typically mild to moderate in intensity. Serious adverse effects may include liver injury, which can present with allergic reactions such as eosinophilia and pruritic rash. Patients should be educated on signs of severe reactions (e.g., jaundice, dark urine) and the need for immediate medical attention. Drug Interactions and Patient Education Maraviroc is metabolized by CYP3A4; interactions with strong inhibitors or inducers can significantly alter drug levels.
Mebendazole does not affect glucose metabolism in humans, making it safe for use.
ANTIVIRAL AGENTS: ACYCLOVIR
Mechanism of Action and Activation Acyclovir inhibits viral replication by suppressing viral DNA synthesis, activated by conversion to acyclo-GMP by thymidine kinase. Acyclo-GMP is further converted to acyclo-GTP, which inhibits viral DNA polymerase and is incorporated into viral DNA, blocking replication. The selectivity of acyclovir is due to its preferential activation in HSV-infected cells, making it less effective against CMV. Indications and Resistance Acyclovir is the first-line treatment for infections caused by HSV and VZV, with varying sensitivity among different herpesviruses. Resistance can develop through decreased thymidine kinase production or alterations in viral DNA polymerase, particularly in immunocompromised patients. Alternative treatments for resistant strains include IV foscarnet or cidofovir, primarily used for CMV infections. Therapeutic Uses of Acyclovir Indicated for mucocutaneous herpes simplex infections, especially in immunocompromised patients.
Oral acyclovir can be used prophylactically to prevent recurrent herpes labialis but is not effective for active outbreaks. Intravenous acyclovir is reserved for severe cases, particularly in immunocompromised individuals.
OVERVIEW OF ACYCLOVIR AND
HERPESVIRUS INFECTIONS
Introduction to Herpesviruses Herpes simplex virus (HSV) and varicella zoster virus (VZV) are part of the herpesvirus family, responsible for various infections. HSV causes infections in the genitalia, mouth, and face, while VZV causes chickenpox and shingles. Shingles results from the reactivation of dormant VZV in sensory nerve roots, leading to painful lesions. Mechanism of Action of Acyclovir Acyclovir inhibits viral replication by suppressing the synthesis of viral DNA. It requires activation to acyclo-guanosine monophosphate (GMP) by thymidine kinase, primarily found in HSV-infected cells. Acyclo-GMP is further converted to acyclo-guanosine triphosphate (GTP), which inhibits viral DNA polymerase and incorporates into viral DNA, blocking replication. Antiviral Spectrum and Resistance Acyclovir is effective against HSV and VZV, with HSV being the most sensitive and CMV showing resistance.
The drug has a half-life of 2.5 hours in patients with normal kidney function, extending to 20 hours in anuric patients. Dosage adjustments are necessary for patients with renal impairment to avoid toxicity.
ADVERSE EFFECTS AND PATIENT
EDUCATION
Adverse Effects of Acyclovir Oral acyclovir is generally well-tolerated, with common side effects including nausea, vomiting, diarrhea, headache, and vertigo. Topical application may cause transient local burning or stinging, but systemic reactions are rare. Intravenous acyclovir can lead to renal failure, particularly in patients with preexisting renal disease or dehydration. Patient Education and Counseling Patients should be informed that acyclovir reduces symptoms but does not eliminate the virus or cure the infection. Advise the use of gloves or finger cots when applying topical acyclovir to prevent viral transfer. Educate patients about the importance of early treatment initiation for optimal outcomes, especially in varicella and herpes zoster cases.
SPECIAL CONSIDERATIONS ACROSS THE
LIFE SPAN
Use in Children and Pregnant Women
Acyclovir is approved for children as young as 3 months; valacyclovir is approved for those 2 years and older. Epidemiological studies show no significant increase in abnormal outcomes for acyclovir use during pregnancy. Foscarnet is not recommended during pregnancy due to potential adverse effects on tooth enamel development. Use in Breastfeeding and Older Adults Acyclovir is excreted in breast milk, with nursing infants receiving a dose of 0.3 mg/kg per day; caution is advised. Valacyclovir results in higher acyclovir levels in breast milk, leading to a dose of 0.6 mg/kg per day for infants. Older adults should be monitored for renal function and CNS effects, with dosage adjustments made as necessary.
OVERVIEW OF ANTIVIRAL DRUGS
Classification of Antiviral Drugs Antiviral drugs are categorized based on the viruses they target, including drugs for herpes simplex virus, cytomegalovirus, hepatitis, influenza, and respiratory syncytial virus. Each class of antiviral drugs has a specific mechanism of action, such as inhibiting viral replication or enhancing immune response. Understanding the classification helps in selecting appropriate treatment options for viral infections. Mechanisms of Action Antiviral drugs can inhibit viral enzymes, block viral entry into host cells, or interfere with viral DNA/RNA synthesis.
Valacyclovir can cause thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients, which can be fatal. Common side effects include nausea, vomiting, diarrhea, headache, and vertigo, similar to those of acyclovir. The FDA recommends caution in dosing for immunocompromised patients, suggesting doses lower than 8 g/day.
DRUGS FOR HEPATITIS
Overview of Hepatitis Treatments Hepatitis treatments include nucleoside analogs, protease inhibitors, NS5A inhibitors, and interferons. Lamivudine is a nucleoside analog used for chronic hepatitis B, while sofosbuvir is an NS5B inhibitor for hepatitis C. Combination therapies are often used to enhance efficacy and reduce resistance. Specific Drugs and Their Mechanisms Simeprevir (protease inhibitor) blocks the NS3/4A protease, preventing viral replication in hepatitis C. Daclatasvir (NS5A inhibitor) interferes with viral replication and assembly. Peginterferon alfa-2a enhances the immune response against hepatitis viruses.
DRUGS FOR INFLUENZA AND
RESPIRATORY SYNCYTIAL VIRUS
Influenza Treatments
Oseltamivir (neuraminidase inhibitor) prevents the release of new viral particles, reducing the duration of influenza symptoms. Baloxavir marboxil (endonuclease inhibitor) works by inhibiting viral RNA synthesis, providing a novel mechanism of action. Vaccination remains the primary method of prevention against influenza. Prophylaxis for Respiratory Syncytial Virus Palivizumab is a monoclonal antibody used for the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. It works by neutralizing the virus and preventing its entry into cells, thus reducing the risk of severe RSV disease. The use of palivizumab is limited to specific populations due to its high cost and limited availability.
TOPICAL ANTIVIRAL TREATMENTS
Topical Drugs for Herpes Labialis Penciclovir cream is indicated for recurrent herpes labialis, applied every 2 hours for 4 days, with modest benefits in healing time. Docosanol cream works by blocking viral entry into host cells and is available over the counter, applied five times a day. Both treatments have limited adverse effects, with docosanol showing no significant side effects. Ocular Antiviral Treatments
Transmission occurs through bodily fluids, making it a significant concern in immunocompromised individuals. CMV can cause severe complications, including retinitis in AIDS patients, leading to vision loss. The virus remains dormant post-infection, posing risks of reactivation. Prophylactic treatments are essential for high-risk patients, especially organ transplant recipients. Understanding CMV's transmission and effects is vital for effective prevention and treatment.
KEY PRESCRIBING CONSIDERATIONS FOR
ANTIVIRAL DRUGS
Baseline Data and Monitoring Baseline assessments include serum creatinine, BUN, urinalysis, and CBC with WBC differential. Drug-specific monitoring is crucial: Acyclovir: liver enzymes, urinalysis for dehydration. Valacyclovir: liver enzymes, urinalysis. Foscarnet: electrolytes, ECG, and 24-hour creatinine clearance. Regular monitoring helps prevent adverse effects and ensures therapeutic efficacy. Adjustments in therapy may be necessary based on monitoring results. Understanding the pharmacokinetics of each drug aids in effective monitoring.
Identifying High-Risk Patients High-risk patients include those with impaired renal function and specific electrolyte imbalances. Foscarnet poses additional risks for patients with QT prolongation and heart failure. Close monitoring of electrolytes is essential for patients on foscarnet. Patient history should include previous reactions to antiviral therapies. Education on recognizing symptoms of adverse effects is crucial for patient safety. Tailoring treatment plans based on individual risk factors enhances therapeutic outcomes.
ANTIVIRAL AGENTS FOR CMV INFECTION
Ganciclovir Ganciclovir is a synthetic antiviral effective against CMV, particularly in immunocompromised patients. Mechanism of action involves conversion to ganciclovir triphosphate, inhibiting viral DNA polymerase. Approved for preventing and treating CMV infections in high- risk populations. Adverse effects include granulocytopenia and thrombocytopenia, necessitating regular blood monitoring. Black Box Warning highlights risks of severe hematologic effects and reproductive toxicity.
Cidofovir: Severe renal impairment can occur, necessitating close monitoring of renal function and contraindications for patients with existing kidney issues. Foscarnet: Renal impairment and seizures related to electrolyte disturbances are significant risks, requiring frequent monitoring of serum electrolytes.
THERAPEUTIC USE AND MONITORING
Indications for Use Cidofovir: Approved solely for CMV retinitis in AIDS patients; efficacy against other CMV infections is uncertain. Foscarnet: Indicated for CMV retinitis in AIDS and acyclovir- resistant HSV/VZV infections. Monitoring Parameters General Monitoring: Regular checks of serum creatinine, electrolytes, and complete blood count (CBC) are essential for all antiviral therapies. Cidofovir: Requires urinalysis for protein and hydration therapy with each infusion to prevent nephrotoxicity. Foscarnet: Needs close monitoring of calcium, magnesium, potassium, and phosphorus levels due to risks of severe imbalances.
VIRAL HEPATITIS OVERVIEW
Types of Hepatitis Viruses Hepatitis viruses A, B, C, D, E, and G can cause acute hepatitis, with B, C, and D also leading to chronic hepatitis.
Hepatitis A: Typically causes acute illness and is preventable by vaccination. Hepatitis B and C: Major causes of chronic liver disease and require antiviral treatment for management. Impact and Prevalence Viral hepatitis is the most common liver disorder in the U.S., affecting millions. Chronic hepatitis can lead to severe complications, including cirrhosis and liver cancer, necessitating early detection and treatment.
OVERVIEW OF HEPATITIS VIRUSES
Types of Hepatitis Viruses Hepatitis viruses are classified into six main types: A, B, C, D, E, and G, each with distinct transmission routes and clinical implications. Hepatitis A (HAV) and E (HEV) are primarily associated with acute infections and are often transmitted through contaminated food and water. Hepatitis B (HBV), C (HCV), and D (HDV) can lead to chronic infections, with significant long-term health consequences. Chronic hepatitis is primarily caused by HBV and HCV, accounting for 90% of cases, leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma. The prevalence of HBV and HCV in the U.S. is approximately 1.5%, significantly higher than HIV infection rates.
